ECD Proteins
SKU: PME100095 Target: Her2
Price: 10μg $85.00; 50μg $310.00 ; 100 μg $460.00
ECD Proteins
SKU: PME100665 Target: Her2
Price: 10μg $78.00; 50μg $310.00 ; 100 μg $460.00
ECD Proteins
SKU: PME-C100074 Target: Her2
Price: 10μg $78.00; 50μg $310.00 ; 100 μg $460.00
Posts found
HER2 | A Key Target in Solid Tumor Therapy
On November 20, 2024, Jazz Pharmaceuticals announced that the bispecific antibody Zanidatamab had received accelerated [...]
Feb
Dual-Payload ADCs: The Next Big Thing in the ADC Arena
Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, [...]
Apr
Popular Targets in the Bispecific ADC Pipeline
At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such [...]
Apr
China’s Growing Impact on ADC Development at AACR 2025
The 2025 American Association for Cancer Research (AACR) Annual Meeting is set to take place [...]
Apr
Going Nuclear: The Boom of Radiopharmaceutical Targets in 2024
In 2024, the radiopharmaceutical sector has seen a flurry of activity in mergers and acquisitions. [...]
Oct
HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond
On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a [...]
Sep
Nectin-4: A Promising Target in Antibody-Drug Conjugate (ADC) Therapy
During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the [...]
Jun
Emerging Trends: ADC Drug Targets to Watch at ASCO 2024
The 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) will take place in [...]
May
Navigating the ADC Frontier: Unleashing the Magic of Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) have been one of the hottest areas in the biopharmaceutical industry in [...]
Apr
Can AXL Break Through in Tumor Immunotherapy with Setbacks in AXL-ADC?
At the end of 2020, Genmab and ADC Therapeutics announced the termination of clinical development [...]
Dec